Multi-center, open-label study for eligible patients who completed Study TDE-HF-301. The primary objective of this study is to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301. The secondary objective of this study is to assess the effect of continued long-term therapy with oral treprostinil on the following:
- 6-Minute Walk Distance (6MWD)
- Borg dyspnea score
- World Health Organization (WHO) Functional Class
- N-Terminal pro-brain natriuretic peptide (NT-proBNP) at Weeks 24 and 48.